Nitro Pohl (Glyceryl Trinitrate)

Glyceryl trinitrate is converted in the body to nitric oxide, a potent vasodilator. Nitric oxide activates soluble guanylate cyclase, increasing cyclic GMP within smooth‑muscle cells. Elevated cyclic GMP causes relaxation of vascular smooth muscle, producing venous and arterial dilation, reduced preload and afterload, and relief of coronary artery spasm.

The specific dose and infusion rate of Nitro Pohl are determined by the prescribing clinician based on the patient’s condition, hemodynamic status, and response to therapy. Dosing is individualized and should follow institutional protocols and the product’s prescribing information.

The safety of glyceryl trinitrate in pregnancy and lactation has not been definitively established. It is generally classified as a category where benefits must outweigh potential risks, and use is reserved for situations where alternative treatments are unsuitable. Clinicians should evaluate each case carefully.

To order Nitro Pohl, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Nitro Pohl contains glyceryl trinitrate, which is chemically identical to nitroglycerin and shares the same mechanism of nitric‑oxide donation. The main differences lie in formulation and regulatory status; Nitro Pohl is supplied as a sterile intravenous solution meeting EU GMP standards, whereas other products may be available in different concentrations or dosage forms.

Store Nitro Pohl at ambient temperature, preferably below 25 °C, in its original packaging. Protect the solution from direct light, moisture and extreme temperature fluctuations. Do not freeze or shake the vial, and ensure that any opened container is used within the time frame recommended by the manufacturer.

Nitro Pohl is administered intravenously by a qualified healthcare professional. The solution is typically infused through a calibrated infusion set, with the rate adjusted according to the patient’s blood‑pressure response and clinical condition. Continuous monitoring of vital signs is essential throughout the infusion.

The most serious risks include severe hypotension that can lead to syncope or organ hypoperfusion, methemoglobinemia causing impaired oxygen delivery, and life‑threatening cardiac arrhythmias. Prompt recognition and management of these events are critical, and the drug should be discontinued if they occur.

Nitro Pohl should be avoided in patients with known hypersensitivity to glyceryl trinitrate or other nitrates, those who have taken phosphodiesterase‑5 inhibitors within the past 24‑48 hours, and individuals with severe aortic stenosis or uncontrolled hypotension. Contraindications must be confirmed before initiating therapy.